← LEXICON PHARMACEUTICALS, INC. (LXRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
LEXICON PHARMACEUTICALS, INC. (LXRX)
Pharmaceutical Preparations · market cap $926M · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
17
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Lexicon Pharmaceuticals (LXRX) is a small-cap biopharma with 225 employees and a ~$1.06B market cap trading at ~$2.39/share. The company's lead asset is sotagliflozin, a dual SGLT1/2 inhibitor in Phase 3 for Type 2 Diabetes, alongside a broad pipeline including LX9211 (Phase 2, diabetic peripheral neuropathic pain) and several other Phase 2 candidates. With only $38.1M in cash and a runway of ~7.8 months, near-term financing risk is acute.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-01-15 (est.)Phase 3 · Sotagliflozinimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| LX9211 | Phase 2 | Diabetic Peripheral Neuropathy |
| LX4211 Low Dose | Phase 2 | Type 2 Diabetes Mellitus |
| LX3305 low dose | Phase 2 | Rheumatoid Arthritis |
| 75 mg LX4211 | Phase 2 | Type 2 Diabetes Mellitus |
| 250 mg LX1033 tablets | Phase 2 | Irritable Bowel Syndrome |
| Sotagliflozin (SAR439954) | Phase 3 | Type 2 Diabetes Mellitus |
| LX6171 High Dose | Phase 2 | Age-Related Memory Disorders |
| Sotagliflozin | Phase 3 | Type 2 Diabetes Mellitus |
| LX7101 (0.125%) | Phase 2 | Primary Open-angle Glaucoma |
| Sulfonylurea | Phase 3 | Type 2 Diabetes Mellitus |
| LX1031 High Dose | Phase 2 | Irritable Bowel Syndrome |
| Telotristat etiprate | Phase 3 | Carcinoid Syndrome |
| Insulin glargine (HOE901) | Phase 3 | Type 2 Diabetes Mellitus |
| LX9211 (blinded) | Phase 2 | Diabetic Peripheral Neuropathic Pain |
| Volagidemab | Phase 2 | Type 1 Diabetes |
| Telotristat Ethyl | Phase 2 | Locally Advanced Unresectable Pancreatic Adenocarcinoma |
| Glimepiride | Phase 3 | Type 2 Diabetes Mellitus |
Price & technical context
3-month
-21.6%
6-month
+11.0%
12-month
+29.1%
52-wk range
$1.14–$2.64
vs 50-day MA
-17.6%
vs 200-day MA
-1.2%
Realized vol
76.2%
Max drawdown
-86.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LXRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.